If you are taking Combivir as well as interferon with or without ribavirin and you experience new side effects, tell your health care provider. While taking Combivir, it is important to keep all of your appointments with your health care provider. Combivir is a prescription medicine approved by the U. Combivir is always used in combination with other HIV medicines. Combivir contains two different medicines: lamivudine and zidovudine.
Take Combivir by mouth with or without food. Tell your health care provider if your child has trouble swallowing Combivir tablets. If you take too much Combivir, contact your health care provider or local poison control center right away, or go to the nearest hospital emergency room. For more information on how to take Combivir, see the FDA drug label.
If you miss a dose of Combivir, take the missed dose as soon as you remember it. But if it is almost time for your next dose, skip the missed dose and just take your next dose at the regular time. Do not take two doses at the same time to make up for a missed dose.
Combivir may cause side effects. Some side effects of Combivir can be serious as noted above. Many side effects from HIV medicines, such as nausea or occasional dizziness, are manageable. Tell your health care provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Combivir.
To learn more about possible side effects of Combivir, read the drug label or package insert or talk to your health care provider or pharmacist.
Get the latest public health information from CDC. Drug Database Search Drug Database search. Anthelmintic Benzimidazole. Antibacterial Glycopeptide. Antibacterial Lincosamide. Antibacterial Macrolide. Antibacterial Quinolone. Antibacterial Sulfonamide. Antifungal Azole. Antifungal Imidazole. Antifungal Nucleoside Analog. Antifungal Polyene. Antimalarial Aminoquinoline. Antimalarial Dihydrofolate Reductase Inhibitor. Antimycobacterial Cyclic Peptide. Antimycobacterial Rifamycins.
Antiviral Interferon Alpha. Antiviral Nucleoside Analog. Attachment Inhibitor. Broadly Neutralizing Antibodies. Capsid Inhibitors. CCR5 Antagonist. CD4 Attachment Inhibitor. Combination Drugs.
Fusion Inhibitor. Gene Therapy Products. Immune Globulins. The first fixed dose combination antiretroviral Combination antiretroviral therapy, sometimes called highly active combination therapy HAART has revolutionized the management of HIV infection and rendered it a chronic manageable disease Palella References Antiretroviral pregnancy register steering committee. Antiretroviral pregnancy registry international interim report 1 January —31 July Wilmington, MC: Registry coordinating centre; A case-control study of HIV seroconversion in health care workers after percutaneous exposure.
N Engl J Med. A syndrome of lipoatrophy, lactic acidaemia and live dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor related lipodystrophy syndrome.
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Combination antiretroviral strategies for the treatment of pregnant HIVinfected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. Assessing teratogenicity of antiretroviral drugs: monitoring and analysis plan of the Antiretroviral Pregnancy Registry.
Pharmacoepidemiol Drug Saf. CNA Study Team. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine with zidovudine alone in HIV-infected individuals.
Antiviral Ther. A double-blind, placebo-controlled trial. Antimicrob Agents Chemother. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Triple-nucleoside regimens versus efavirenz containing regimens for initial treatment of HIV-1 infection.
Clinical risk factors for hypersensitivity reactions to abacavir: retrospective analysis of over 8, subjects receiving abacavir in 34 clinical trials. Abstract H A randomised controlled comparison with zidovudine monotherapy.
Mitochondrial Toxicity Study Group. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
Centres for Disease Control and Prevention, U. Public Health Service Task Force. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Eng J Med. The K65R mutation in human immunodeficiency type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
J Virol. J Infect Dis. Abstract no Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med. Comparisons of sequential three-drug regimens as initial therapy for HIV-1 infection. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine experienced patients. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
Abstract no Mo. Antimicrob agents Chemother. For the full list of all the side effects of Combivir and restrictions on its use, see the package leaflet. The CHMP considered that combining the active ingredients in a single tablet may be of advantage because it can improve how well patients stick to the prescribed treatment and this can help to prevent HIV becoming resistant to treatment.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Combivir have been included in the summary of product characteristics and the package leaflet. For more information about treatment with Combivir, read the package leaflet also part of the EPAR or contact your doctor or pharmacist. More detail is available in the summary of product characteristics.
Combivir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus HIV infection see section 4. Please do not include any personal data , such as your name or contact details. Skip to main content. Veterinary regulatory Overview Research and development Marketing authorisation Post-authorisation. Combivir RSS. Table of contents Overview Authorisation details Product information Assessment history.
Expand section Collapse section. Combivir is available as tablets containing lamivudine mg and zidovudine mg. Authorisation details. Product details Name Combivir.
Product information. List item. You are therefore advised to be selective about which sections or pages you wish to print. Antivirals for systemic use. Assessment history.
0コメント